Treatment of Hypogonadism: Current and Future Therapies [version 1; referees: 2 approved]

Arthi Thirumalai; Kathryn E. Berkseth; John K. Amory

doi:10.12688/f1000research.10102.1

F1000Research (Jan 2017)

Treatment of Hypogonadism: Current and Future Therapies [version 1; referees: 2 approved]

Arthi Thirumalai,
Kathryn E. Berkseth,
John K. Amory

Affiliations

Arthi Thirumalai: Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
Kathryn E. Berkseth: Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA
John K. Amory: Center for Research in Reproduction and Contraception, Department of Medicine, University of Washington, Seattle, WA, USA

DOI: https://doi.org/10.12688/f1000research.10102.1
Journal volume & issue: Vol. 6

Abstract

Read online

The treatment of hypogonadism in men is of great interest to both patients and providers. There are a number of testosterone formulations currently available and several additional formulations under development. In addition, there are some lesser-used alternative therapies for the management of male hypogonadism, which may have advantages for certain patient groups. The future of hypogonadism therapy may lie in the development of selective androgen receptor modulators that allow the benefits of androgens whilst minimizing unwanted side effects.

Published in F1000Research

ISSN: 2046-1402 (Online)
Publisher: F1000 Research Ltd
Country of publisher: United Kingdom
LCC subjects: Medicine; Science
Website: https://f1000research.com

About the journal

Abstract

Keywords